RxDoctor Payments Data

Daniel Lee, MD

Ophthalmology · Turlock, CANPI 1295823755

Payments from drug & device makers

$3,955in general payments, 2019–2025

Across 160 payments — averaging $24.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$880
  • Glaukos Corporation$690
  • Aerie Pharmaceuticals, Inc.$279
  • Amgen$203
  • Novartis$141
  • plus $514 from 10 others

What the payments were for

  • Food & beverage$3,937100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,955 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$938,452
Medicare patients
1,915
Services billed
8,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost174$81,308
RocklatanNetarsudil Mesylat/Latanoprost113$68,379
Prednisolone Acetate1,524$43,194
RestasisCyclosporine20$27,351
CequaCyclosporine27$26,397
MoxifloxacinMoxifloxacin Hcl1,293$25,503
RhopressaNetarsudil Mesylate37$21,150
Azelastine Hcl540$18,737
Latanoprost996$16,456
CombiganBrimonidine Tartrate/Timolol21$10,787
Travoprost52$8,758
Timolol Maleate441$7,194
VyzultaLatanoprostene Bunod16$6,566
Timolol MaleateTimolol Maleate/Pf12$6,537
Alphagan PBrimonidine Tartrate16$4,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$880$124,311231 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$279$89,529150 claims
Sun Pharmaceutical Industries Inc.Cequa$84$26,39727 claims
Bausch & Lomb Americas Inc.Vyzulta$90$6,56616 claims
AlconSimbrinza$1,248$4,04113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →